A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE)
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Tarextumab (Primary) ; Carboplatin; Cisplatin; Etoposide
- Indications Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms PINNACLE
- Sponsors OncoMed Pharmaceuticals
- 09 Apr 2019 Status changed from to discontinued.
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
- 17 Apr 2017 According to an OncoMed Pharmaceuticals media release, company plans to present full study findings, including results from the biomarker analyses from this trial at a future scientific conference.